RAD Doses First Patient in Second Cohort of BetaBart (RV-01)
Filed with ASX · · 2 pages · English
Radiopharm Theranostics Limited on 6ix
Story so far
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
- RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial
- Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Earlier from Radiopharm Theranostics
- Ceasing to be a substantial holder
- Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
- RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial
- Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
- Change in substantial holding
Later from Radiopharm Theranostics
- Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
- Change of Director's Interest Notices x 4
- Appendix 4E and Preliminary Final Report
- RAD Announces Positive Data from RAD301 P1 Imaging Trial
- Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics